Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
Authors
Bach Ardalan
University of Miami, Miami, FL;
Bach Ardalan , Aaron Ciner , Yasmine Baca , Sourat Darabi , Anup Kasi , Emil Lou , Jose Ignacio Azqueta , Joanne Xiu , Chadi Nabhan , Anthony Frank Shields , Michael J. Pishvaian , Wolfgang Michael Korn , Sanjay Goel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 735)
DOI
10.1200/JCO.2023.41.4_suppl.735
Abstract #
735
Poster Bd #
M2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
First Author: Bach Ardalan
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2020 ASCO Virtual Scientific Program
Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies.
First Author: Andrew Eugene Hendifar
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Carter Norton